What is the 13F Pro Quality Score for RNAC?

13F Pro ranks Cartesian Therapeutics, Inc. (RNAC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RNAC's current score at https://13fpro.ai/research/RNAC (free sign-up required for the full ranking).

Which hedge funds own the most RNAC stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RNAC include Squarepoint Ops, FMR, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RNAC as soon as new 13F filings post.

Where does 13F Pro source RNAC data?

All Cartesian Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cartesian Therapeutics, Inc. files with the SEC under CIK 1453687. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RNAC in?

Cartesian Therapeutics, Inc. (RNAC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RNAC research updated on 13F Pro?

RNAC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cartesian Therapeutics, Inc.(RNAC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1453687 RNAC stock profile & AI dashboard →

13F Pro Quality Score

7.5/100

Rank #2,835 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

1.1/100

Profitability

0.3/100

Balance Sheet

8.9/100

Earnings Quality

30.0/100

Free Cash Flow

0.2/100

Institutional Flow

83.9/100

Revenue Scale

0.3/100

Dilution Risk

1.3/100

RNAC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cartesian Therapeutics, Inc. (RNAC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RNAC at 7.5/100 on a 32-signal composite quality model, placing it at rank #2,835 of 2,879 stocks — the bottom half of the AI-ranked universe. RNAC scores in the top quartile across institutional flow (83.9). Areas of concern include free cash flow (0.2) and profitability (0.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Cartesian Therapeutics, Inc. reports quarterly revenue of $78.0K, net income of $-39.2M, free cash flow of $-22.2M. Top institutional holders of RNAC by reported 13-F value include Squarepoint Ops, FMR, BlackRock,, based on the most recent SEC filings. RNAC trades on the Nasdaq exchange and files with the SEC under CIK 1453687. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNAC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cartesian Therapeutics, Inc. directly from SEC EDGAR. Cartesian Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 13 since 2024, currently 7.5 — a declining long-term trajectory across 18 quarterly and live scoring snapshots.

Revenue

Q1 2026

$78.0K

Net Income

Q1 2026

$-39.2M

Free Cash Flow

Q1 2026

$-22.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-97.5% YoY

$2.8MFY 2025

FY20 $16.6MFY21 $85.1MFY22 $110.8MFY25 $2.8M

Net Income

-468.3% YoY

$-130.3MFY 2025

FY20 $-68.9MFY21 $-25.7MFY22 $35.4MFY25 $-130.3M

Operating Income

-1086.4% YoY

$-143.4MFY 2025

FY20 $-56.8MFY21 $-4.6MFY22 $14.5MFY25 $-143.4M

EPS (Diluted)

-5120.0% YoY

$-5.02FY 2025

FY20 $-0.68FY21 $-0.22FY22 $0.10FY25 $-5.02

Total Assets

+78.7% YoY

$296.4MFY 2025

FY20 $165.4MFY21 $159.9MFY22 $165.9MFY25 $296.4M

Op. Cash Flow

-133.8% YoY

$-73.9MFY 2025

FY20 $34.9MFY21 $-60.4MFY22 $-31.6MFY25 $-73.9M

Metric	FY 2025	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$2.8M -97.5%	$110.8M +30.2%	$85.1M +412.6%	$16.6M +148.6%	$6.7M +639.4%	$903.0K
Net Income	$-130.3M -468.3%	$35.4M +237.7%	$-25.7M +62.7%	$-68.9M -24.4%	$-55.4M +15.3%	$-65.3M
Operating Income	$-143.4M -1086.4%	$14.5M +416.2%	$-4.6M +91.9%	$-56.8M -8.3%	$-52.5M +19.3%	$-65.0M
EPS (Diluted)	$-5.02 -5120.0%	$0.10 +145.5%	$-0.22 +67.6%	$-0.68 +44.3%	$-1.22	—
Total Assets	$296.4M +78.7%	$165.9M +3.8%	$159.9M -3.4%	$165.4M +66.2%	$99.6M +123.8%	$44.5M
Operating Cash Flow	$-73.9M -133.8%	$-31.6M +47.6%	$-60.4M -273.1%	$34.9M +167.8%	$-51.4M +13.1%	$-59.2M

AI Insight: RNAC Financial Trends

Cartesian burns through equity while operating losses accelerate, with negative shareholders' equity of $148M in Q1 2026.

• Revenue remains minimal at $0-1M per quarter despite early Q2 2024 spike of $33M.

• Operating losses worsened from $-18M in Q3 2024 to $-79M in Q4 2025.

• Shareholders' equity deteriorated from $1M in Q3 2024 to negative $148M in Q1 2026.

⚠ Consistent negative operating cash flow averaging $18M quarterly burn rate threatens liquidity.

⚠ Q4 2025 recorded largest quarterly net loss of $93M, suggesting accelerating cash burn.

AI Insight: RNAC Ratio Trends

ROA volatility with deep deterioration to -54.4% in Q1 2026 signals operational instability for this biotech.

• ROA swung wildly from 16.3% in Q2 2025 to -54.4% in Q1 2026, showing extreme quarterly volatility.

• Operating margin of 41.1% and net profit margin of 41.4% in Q2 2024 disappeared in subsequent quarters.

⚠ TTM ROA of -52.6% through Q1 2026 reflects sustained losses across the trailing four quarters.

⚠ Missing financial metrics across most periods suggest irregular reporting or operational disruptions.

Get alerted when RNAC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cartesian Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RNAC

Squarepoint Ops LLC
$13.8M2,238,486 sh
FMR LLC
$4.9M799,743 sh
BlackRock, Inc.
$3.7M599,108 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.5M407,597 sh
683 Capital Management, LLC
$2.0M330,000 sh
MILLENNIUM MANAGEMENT LLC
$1.7M284,317 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.6M263,694 sh
MARSHALL WACE, LLP
$1.5M251,115 sh
Erste Asset Management GmbH
$1.3M221,705 sh
STATE STREET CORP
$1.2M200,337 sh

Fund	Value	Shares
Squarepoint Ops LLC	$13.8M	2,238,486
FMR LLC	$4.9M	799,743
BlackRock, Inc.	$3.7M	599,108
VANGUARD CAPITAL MANAGEMENT LLC	$2.5M	407,597
683 Capital Management, LLC	$2.0M	330,000
MILLENNIUM MANAGEMENT LLC	$1.7M	284,317
GEODE CAPITAL MANAGEMENT, LLC	$1.6M	263,694
MARSHALL WACE, LLP	$1.5M	251,115
Erste Asset Management GmbH	$1.3M	221,705
STATE STREET CORP	$1.2M	200,337

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RNAC on your watchlist

Track score changes the day Cartesian Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RNAC a good stock to buy?

13F Pro's AI-powered analysis of Cartesian Therapeutics, Inc. (RNAC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RNAC are available on the RNAC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RNAC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RNAC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cartesian Therapeutics, Inc.'s investment landscape.